<DOC>
	<DOCNO>NCT00006475</DOCNO>
	<brief_summary>RATIONALE : STI571 may interfere growth cancer cell may effective treatment leukemia . PURPOSE : Phase II trial study effectiveness STI571 treat patient chronic myelogenous leukemia blast crisis .</brief_summary>
	<brief_title>STI571 Treating Patients With Chronic Myelogenous Leukemia Blast Crisis</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety profile STI571 patient chronic myelogenous leukemia blast crisis . II . Provide expand access treatment patient . III . Determine rate hematological response duration response patient treat regimen . IV . Determine improvements symptomatic parameter patient treat regimen . V. Determine cytogenetic response patient treat regimen . VI . Determine overall survival patient treat regimen . OUTLINE : This expanded-access , multicenter study . Patients receive oral STI571 daily . Treatment continue 1 year absence disease progression unacceptable toxicity . Patients consider benefit may continue treatment beyond 1 year . PROJECTED ACCRUAL : Not determine</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia ( CML ) blast crisis , define least one following : 30 % blast peripheral blood and/or bone marrow Flow cytometry criterion Extramedullary disease spleen , lymph node , and/or liver involvement Newly diagnose CML blast crisis OR CML blast crisis prior therapy accelerate blastic phase Philadelphia ( Ph ) chromosome positive OR Ph chromosome negative Bcr/Abl positive PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : SGOT SGPT great 3 time upper limit normal ( ULN ) ( great 5 time ULN liver involvement ) Bilirubin great 3 time ULN Renal : Creatinine great 2 time ULN Cardiovascular : No grade 3 4 cardiac disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 2 week study woman least 3 month study men No history noncompliance medical regimens No serious concurrent medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : At least 48 hour since prior interferon alfa At least 6 week since prior hematopoietic stem cell transplantation No concurrent anticancer biologic therapy Chemotherapy : At least 6 week since prior busulfan At least 24 hour since prior hydroxyurea At least 2 week since prior homoharringtonine At least 1 week since prior lowdose cytarabine ( le 30 mg/m2 every 1224 hour daily ) At least 2 week since prior moderatedose cytarabine ( 100200 mg/m2 57 day ) At least 4 week since prior highdose cytarabine ( 13 g/m2 every 1224 hour 612 dos ) At least 3 week since prior anthracyclines , mitoxantrone , etoposide No concurrent anticancer chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 4 week since prior investigational agent No concurrent anticancer investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
</DOC>